What is Palmitoyl Pentapeptide-4?
Palmitoyl Pentapeptide-4 (trade name MATRIXYL, also called Pal-KTTKS or palmitoyl pentapeptide-3 in older nomenclature) is a palmitic-acid-conjugated procollagen fragment developed by Sederma (a Croda business) and introduced commercially in 2002. It was the original Matrixyl peptide and remains one of the most widely-used cosmetic peptides globally.
It is distinct from Matrixyl 3000 (which is a blend of palmitoyl tetrapeptide-7 + palmitoyl oligopeptide). Both products are commercially marketed as "Matrixyl"; understanding the difference matters for formulation and clinical interpretation:
- Matrixyl (original) = Palmitoyl Pentapeptide-4 = Pal-KTTKS
- Matrixyl 3000 = palmitoyl tetrapeptide-7 + palmitoyl oligopeptide
- Matrixyl Synthe'6 = palmitoyl tripeptide-38
This entry covers the original Matrixyl (Pal-KTTKS).
Structure
Palmitoyl Pentapeptide-4 consists of:
- KTTKS pentapeptide — Lys-Thr-Thr-Lys-Ser, derived from the N-propeptide of type I procollagen (residues 197-201)
- Palmitic acid (C16 fatty acid) conjugated to the N-terminal lysine ε-amino group
The palmitoyl moiety provides:
- Lipophilicity for stratum corneum penetration
- Membrane affinity for cell uptake
- Stability against degradation
Mechanism of Action
KTTKS is a fragment released during natural type I procollagen processing. The pentapeptide functions as a feedback signal to dermal fibroblasts:
- Stimulates type I collagen synthesis — fibroblasts respond to the procollagen-derived signal by upregulating collagen production
- Stimulates fibronectin synthesis — supports dermal extracellular matrix
- Inhibits MMP-1 (matrix metalloproteinase-1) — reduces collagen breakdown
- Net effect: increased dermal collagen content with topical application
The palmitoyl conjugation is essential for topical efficacy — it enables stratum corneum penetration and increases cellular uptake by orders of magnitude over the unmodified pentapeptide.
Clinical Evidence
British Journal of Dermatology 2005 (Robinson et al.):
- Randomized controlled trial of topical Pal-KTTKS for photoaged skin
- 12-week twice-daily application
- Significant improvement in fine lines, wrinkles, and skin roughness
- Comparable efficacy to retinol and other established anti-aging actives
- Excellent tolerability vs retinol
These data established Matrixyl as a clinically validated cosmetic active and drove its widespread adoption in commercial skincare.
Cosmetic Use
Palmitoyl Pentapeptide-4 is incorporated into anti-aging skincare at typical concentrations of 3-10% Matrixyl solution (where the solution contains ~0.1% peptide active). Marketed for:
- Fine lines and wrinkles
- Photoaged skin
- Loss of firmness
- Crepey texture
It is often combined with vitamin C, retinol, hyaluronic acid, and other actives in multi-step regimens. Effects are subtle but cumulative over weeks of consistent use.
Place in the Matrixyl Family
| Product | Composition | Mechanism Focus |
|---|---|---|
| Matrixyl (original, Pal-KTTKS) | Palmitoyl Pentapeptide-4 | Type I procollagen feedback |
| Matrixyl 3000 | Pal-Tetrapeptide-7 + Pal-Oligopeptide | NF-κB inhibition + MMP modulation |
| Matrixyl Synthe'6 | Palmitoyl Tripeptide-38 | Six-protein dermal stimulation |
All three products are marketed as "Matrixyl" but contain different actives. Matrixyl 3000 is included in our database under that name; this entry covers the original Pal-KTTKS Matrixyl.
Safety Profile
Excellent safety profile in commercial use over 20+ years:
- No documented systemic absorption to clinically meaningful levels
- Rare contact irritation
- Suitable for daily long-term use
- No known interactions
Why It Matters
Pal-KTTKS was a foundational cosmetic peptide that demonstrated the feasibility of topical peptide drug delivery for dermal anti-aging. Its commercial success drove the development of an entire family of palmitoyl-conjugated cosmetic peptides and helped establish the modern anti-aging skincare category.